Background {#Sec1}
==========

In public health and medicine, Health-Related Quality of Life (HRQoL) measurements have become an important outcome measure in addition to morbidity and mortality rates, both in population health assessment and in clinical trials \[[@CR1], [@CR2]\]. HRQoL is a multi-dimensional concept that includes domains related to physical, mental, emotional, and social functioning. It goes beyond direct measures of population health, life expectancy and causes of death, and focuses on the impact that health status has on Quality of Life (QoL) \[[@CR2]\]. In addition to its multidimensional nature, one important reason to measure the HRQoL is establishing and expanding information about the range of problems that affect the patients \[[@CR3]--[@CR5]\].

In general, chronic diseases are increasingly widespread \[[@CR6]\]. The World Health Organization (WHO), therefore, prioritizes HRQoL improvement for people living with chronic diseases \[[@CR7]\]. In France, the August 9, 2004 public health law applied this priority, implementing a national plan to improve the HRQoL for people living with chronic diseases, mainly those with End-Stage Renal Disease (ESRD) \[[@CR8]\]. The French Biomedicine Agency and the National Institute for Public Health Surveillance have promoted studies to determine the level of HRQoL of ESRD patients in France in order to improve the HRQoL of chronic disease patients \[[@CR9], [@CR10]\].

When compared with dialysis, renal transplantation has become the most cost-effective treatment \[[@CR11]--[@CR13]\] for ESRD patients, as it presents medical costs reduction, extended lifetime \[[@CR14]\] and enhanced HRQoL \[[@CR11], [@CR15], [@CR16]\].

Although the HRQoL advantages in Kidney Transplant Recipients (KTR) were established \[[@CR11], [@CR14], [@CR16]--[@CR21]\], life after kideny transplantation may present negative as well as positive aspects. Therefore, it is essential to describe the demographic and clinical factors that influence HRQoL outcomes. Furthermore, most published studies did not clearly explore the psycho-social variables that potentially can affect the QoL. This study aims to identify factors associated with HRQoL through a comprehensive analysis of demographic, psycho-social and clinical characteristics among a representative cohort of KTR living in France.

Methods {#Sec2}
=======

Study design and patients {#Sec3}
-------------------------

This is a cross-sectional design retrieved from a longitudinal study carried out continuously during the year 2011, in five French kidney transplant centers: Marseille, Montpellier, Nice, Paris and Nantes University Hospitals. All patients aged 18 years and older with a functioning graft for at least one year were eligible for the study. Multi-organ transplant patients before or simultaneously with their kidney transplant were excluded.

Data collection and measures {#Sec4}
----------------------------

Patients were included in 2011 during their regular medical visits. Data of inclusion, including demographic, psycho-social characteristics and HRQoL, were directly collected from the patients who agreed to participate, except health data which were obtained from nephrologists.

### Demographic and psycho-social characteristics {#Sec5}

Demographic and psycho-social variables collected were:

➢ Age, gender, level of education: primary or less, college, secondary 1st stage and university

➢ Living arrangement: alone or not alone

➢ Having children or not, employment status: employed, retired, unemployed

➢ Disability pension: patients receiving disability pension or not

➢ Monthly incomes in the household (€)

➢ Internet and social network use

➢ Social support: done by a perceived questionnaire, used to estimate the availability and the quality of this support \[[@CR22]\]. It is composed of four main scales: esteem, financial, informative and emotional supports. For each scale, patients were asked to answer if they were in need for this support or not.

### Clinical characteristics {#Sec6}

Medical measures were grouped into four domains related to kidney disease, health status and comorbidities, treatments (i.e. drugs) along with their side effects and biological data.To explore kidney disease: we collected the etiology of End-Stage Renal Disease (ESRD), the previous dialysis treatment and duration, the duration since transplantation, the organ donor type (cardiac death, deceased or living-related donor), the organ transplantation (one or two simultaneous kidney grafts), the number of transplantations, the graft rejection episodes and the graft chronic dysfunction.To explore health status and comorbidities: we collected the pathologies frequently associated with KTR (neoplasia, hypertension, and diabetes mellitus), smoking status, Body Mass Index (BMI) and the two validated scales: The Karnofsky Performance Scale (KPS) and The Charlson Comorbidity Index (CCI).

The Karnofsky Performance Scale (KPS) was evaluated to classify patients according to their functional impairment from 0 to 100%. The lower the Karnofsky score, the worse the survival for most serious illnesses was \[[@CR23], [@CR24]\].

The Charlson Comorbidity Index (CCI) was evaluated to classify patient's comorbidities. According to Charlson et al. \[[@CR25]\], the CCI was calculated by assigning for each pathology a score of 1, 2, 3, or 6, depending on the death risk associated with each one and by summing the weights for all present comorbid conditions (ranges from 0 to 37). For the combined age-comorbidity score, each decade of age over 40 adds 1 point to the risk (e.g. 50--59 years, 1 point; 60--69 years, 2 points; 70--79 years, 3 points...) \[[@CR26]\]. Higher scores indicate greater comorbidity.3.To explore treatments and their side effects, we collected treatment characteristics. We generated with nephrologists a selective list of the most commonly prescribed drugs with their generic names, previously used in a recent publication \[[@CR27]\]. This list includes the most used categories of treatments by KTR: immunosuppressive, antihypertensive and other treatments. For each category, we obtained its corresponding drugs. Then, we asked the patients for the existence of side effects related to treatments, without specifying the type.4.To explore biological data: we collected creatinine and hemoglobin (Hb) levels directly from nephrologists during the medical visit. Creatinine levels were defined by establishing 3 categories with nephrologists (normal \< 120 μmol/L, mild to moderate: 120--250 μmol/L, severe \> 250 μmol/L). Anemia was defined by using the World Health Organization (WHO) criteria, which meant that the Hb concentration was below 12 g/dl in women and below 13 g/dl in men \[[@CR28]\].

### Health-related quality of life {#Sec7}

HRQoL was measured with the SF-36 and the ReTransQol. French version of the SF-36 \[[@CR29], [@CR30]\] is a generic, self-administered, multidimensional and coherent measure of HRQoL that consists of 36 items, which are used to calculate eight subscales: Physical Functioning (PF), Role Physical (RP), Bodily Pain (BP), General Health (GH), Vitality (VT), Social Functioning (SF), Role Emotional (RE), and Mental Health (MH). The correlated physical (PCS) and mental (MCS) summary components were computed following the standardized procedure provided by authors \[[@CR27], [@CR31], [@CR32]\].

The ReTransQol version 2 \[[@CR33], [@CR34]\] is a disease specific self-administered instrument assessing the HRQoL of KTR and consisting of 32 items describing 5 dimensions: Physical Health (PH), Mental Health (MH), Medical Care and satisfaction (MC), Treatment (TRT), and Fear of losing the Graft (FG).

Scores for both instruments range from 0 to 100, with higher scores indicating better HRQoL.

Ethical aspects {#Sec8}
---------------

The study methodology was approved by the local Institutional Review Board (CCTIRS n°12-726) and the "Comité National Informatique et Liberté" (CNIL n°1639707), thus ensuring the confidentiality of all the collected informations. All patients agreeing to participate signed a written informed consent before their inclusion in the study.

Statistical analysis {#Sec9}
--------------------

Statistical analysis was performed using Statistical Package for Social Sciences (SPSS) software (version 20, SPSS, Inc., Chicago, IL, USA). Quantitative data were expressed as mean ± standard deviation (SD), minimum and maximum or median, 25th and 75th percentiles, whereas categorical data were expressed as frequency and percentage. Group comparisons were performed using analysis of variance (bivariate analysis) for quantitative variables. All factors with a *p*-value \< 0.2 were included as candidate variables in the multivariate analysis. Multivariate Linear Regression models (MLR) were used to estimate the relationship between HRQoL scores and the other characteristics. The β coefficients and p-value were performed. The level of significance was set at a p-value ≤0.05. The assumptions of the MLR were verified for linear relationship, normality of distribution, absence of multicollinearity and residuals. Because missing data were minimal (\< 10%), we did not replace them and we only analyzed the available ones (i.e. ignoring the missing data).

Results {#Sec10}
=======

At the time of the survey, 1469 KTR met eligible criteria for the study during 2011. Among them, 45 patients (3.1%) without QoL questionnaires were excluded from this study and 1424 were included and selected for analysis. Thus, the participation rate is 96.9%.

Patients' characteristics {#Sec11}
-------------------------

As presented in Table [1](#Tab1){ref-type="table"}, patient's mean age was 55.7 years (± 13.1), more than 60% were males and lived with a partner. Less than 40% attended college and were employed at the time of the survey. The majority of KTR had access to internet in the household. Moreover, most of KTR declared having felt a need for an esteem support more than the other supports.Table 1Patients' characteristics (*N* = 1424)N (%)Gender Male874 (61.4)Age (years) Mean ± SD55.7 ± 13.1 Range18.8--85.9Level of education Primary or less163 (11.5) College536 (37.9) Secondary 1st stage304 (21.5) University413 (29.1)Living arrangement Alone323 (22.7)Children No children390 (27.6)Employment status Employed548 (38.5) Retired545 (38.3) Unemployed329 (23.2)Patients receiving disability pension487 (34.7)Monthly incomes in the household (€) \< 739100 (7.5) 740--1200255 (19.1) 1201--2200419 (31.4) 2201--4400425 (31.8) \> 4400136 (10.2)Internet Patients with Internet use1131 (79.9)  Patients with Social networks use417 (36.9)Perceived social support Patients in need for an esteem support869 (61.1) Patients in need for a financial support377 (26.5) Patients in need for an informative support559 (39.4) Patients in need for an emotional support592 (41.8)*SD* standard deviation

Regarding the clinical characteristics (Table [2](#Tab2){ref-type="table"}), more than a third of KTR had glomerulonephritis and the majority were dialyzed before transplantation. Median time since transplantation was 7.1 years. Most of patients had a deceased donor transplantation and had a single kidney transplantation. The mean CCI score was 4.09 (± 1.8, range from 2 to 14), and most of KTR had mild to moderate creatinine level (50.8%). Other characteristics about clinical characteristics are shown in Table [2](#Tab2){ref-type="table"}. Most patients were treated with immunosuppressive drugs. Nearly 28% of KTR reported side effects related to treatments with a mean number of side effects of 6.4 ± 1.7 per patient (Table [3](#Tab3){ref-type="table"}).Table 2Clinical characteristics: kidney disease, health status, comorbidities and biological dataN (%)Major causes of ESRD Chronic glomerulonephritis487 (34.3) Interstitial nephropathy158 (11.3) Polycystic kidney disease262 (18.8) Other nephropathies (vascular, diabetic...)497 (35.6)Previous dialysis treatment Patient with dialysis treatment1212 (86.8) Duration of dialysis, Median (25th percentiles, 75th percentiles)24 (12, 42)Transplantation Duration of transplantation, Median (25th percentiles, 75th percentiles)7.1 (3.7, 12.8)Organ donor type Cardiac death donor47 (3.4) Deceased donor1231 (88.3) Living-related donor116 (8.3)Organ transplantation1396 (98.0) Only one kidney graft1373 (98.4) Two simultaneously kidney grafts23 (1.6)Kidney Transplants number The first transplant1199 (85.7) The second transplants181 (12.9) Three or more transplants19 (1.4)Patients with at least one acute rejection episode213 (15.3)Patients with chronic graft dysfunction426 (30.6)Comorbidities Neoplasia285 (20.4) Hypertension1143 (81.8) Diabetes mellitus255 (18.2) Smoking patients203 (14.9) BMI \> 30 (kg/m^2^)213 (15.3)Karnofsky Index scale, rating criteria (%) 80--100: Able to carry on normal activity and to work1311 (94.2) 50--70: Unable to work76 (5.5) 20--40: Unable to care for self3 (0.2) 0--10: Death, disease may be progressing rapidly2 (0.1)Charlson Comorbidity Index, score Mean ± SD4.09 ± 1.8 Range2--14Biological dataCreatinine levels (μmol/L) Normal: \< 120583 (42.6) Mild to moderate: 120--250697 (50.8) Severe: \> 25091 (6.6)Hemoglobin levels (g/dl) Anemia: \< 12551 (40.4) Normal: hemoglobin ≥12813 (59.6)*ESRD* End-Stage Renal Disease, *SD* standard deviationTable 3Clinical characteristics: treatments and their side effectsDrugs\
N (%)Side effects^a^\
N (%)Mean number of drugs/side effects per patient6.6 ± 1.8 (2--14)6.4 ± 1.7 (4--9)Immunosuppressive treatments1397 (98.1)344 (24.6) Calcineurin inhibitors1170 (82.2)242 (20.6) Mycophenolic acid and derivatives933 (65.5)115 (12.3) Corticoids832 (58.4)159 (19.1) Others (mTOR inhibitors, Azathioprine)334 (23.4)56 (16.7)Antihypertensive treatments1161 (81.5)72 (6.2) Beta-blockers727 (51.1)28 (3.8) Angiotensin-converting enzyme (ACE) inhibitors709 (49.8)34 (4.8) Calcium antagonists485 (34.1)20 (4.1) Others (Central antihypertensive, Peripheral vasodilators/alpha-blockers, Diuretics)544 (38.2)30 (5.5)Other treatments1170 (82.2)54 (4.6) Cardiovascular drugs792 (55.6)38 (48.0) Calcium drugs727 (51.1)2 (0.3) Diabetes drugs239 (16.8)13 (5,4) Erythropoiesis-Stimulating Agents (ESA)199 (14.0)1 (0.5) Antidepressants149 (10.5)4 (2.7)^a^Percentage of side effects = number of patients with a side effect related to the treatment dividing by number of patients taking this treatment

### Health related quality of life {#Sec12}

Figure [1](#Fig1){ref-type="fig"} shows the mean HRQoL scores and their SD for the eight components of the SF-36 and the five components of the ReTransQol.Fig. 1HRQoL scores (SF36 & ReTransQol)

Multivariate regression analysis {#Sec13}
--------------------------------

We selected all variables in the final regression model for both questionnaires (SF-36 and ReTransQol) according to their significance in the univariate analysis (*p* \< 0.2).

Adjusted differences in the ten generic dimensions of SF-36 and in the five specific dimensions of ReTransQol using demographic, psycho-social and clinical variables are shown in Tables [4](#Tab4){ref-type="table"} and [5](#Tab5){ref-type="table"}, respectively.Table 4Final regression models for SF-36 domainsDimensionsVariablesβ coeff. \[95% CI\]*P* valuesPF\
*N = 1253*\
*R*^*2*^ *= 0.21*Intercept84.1 \[75.3; 92.8\]\< 0.001Age−0.3 \[− 0.4; − 0.1\]\< 0.001Female−4.4 \[−7.0; −1.8\]0.001Disability pension−6.3 \[−9.0; −3.7\]\< 0.001High monthly incomes (€)3.5 \[2.3; 4.7\]\< 0.001Having felt a need for an esteem support−4.1 \[− 6.8; − 1.3\]0.004Having felt a need for a financial support−3.1 \[− 6.1; − 0.1\]0.04Diabetic patient− 4.5 \[− 7.9; − 1.2\]0.008BMI \> 30 (kg/m^2^)− 4.0 \[− 7.4; − 0.6\]0.021Treatment with ESA− 3.7 \[− 7.3; − 0.1\]0.045Treatment with antidepressants−5.7 \[− 9.7; − 1.7\]0.005KPS ≥ 70%16.9 \[11.6; 22.2\]\< 0.001High creatinine levels \> 250 (μmol/L)− 2.7 \[− 4.8; − 0.6\]0.012CCI score− 1.4 \[− 2.4; − 0.4\]0.005RP\
*N = 1256*\
*R*^*2*^ *= 0.14*Intercept84.0 \[69.0; 99.0\]\< 0.001Age−0.4 \[− 0.5; − 0.2\]\< 0.001Disability pension− 7.4 \[− 12.0; − 2.7\]0.002High monthly incomes (€)4.5 \[2.5; 6.5\]\< 0.001Having felt a need for an esteem support−6.4 \[− 11.5; − 1.3\]0.015Having felt a need for an emotional support−8.4 \[−13.6; − 3.3\]0.001Diabetic patient−6.2 \[−11.7; − 0.8\]0.026Treatment with ESA−8.9 \[−15.0; −2.7\]0.005Treatment with antidepressants−15.2 \[− 22.2; − 8.2\]\< 0.001KPS ≥ 70%14.6 \[5.5; 23.6\]0.002High creatinine levels \> 250 (μmol/L)−5.9 \[−9.4; − 2.4\]0.001BP\
*N = 1257*\
*R*^*2*^ *= 0.15*Intercept85.3 \[74.7; 95.9\]\< 0.001Age−0.3 \[− 0.4; − 0.2\]\< 0.001Female−4.6 \[−7.7; −1.5\]0.003Having children−3.9 \[− 7.4; − 0.4\]0.03Disability pension−6.3 \[−9.5; −3.1\]\< 0.001High monthly incomes (€)1.8 \[1.4; 3.3\]0.014Having felt a need for an esteem support−5.2 \[−8.5; −1.9\]0.002Diabetic patient−6.0 \[−9.8; −2.2\]0.002Treatment with cardiovascular drugs−3.8 \[−6.9; −0.7\]0.017Treatment with antidepressants−9.6 \[− 14.4; −4.7\]\< 0.001Side effects related to any treatment−5.8 \[− 9.0; − 2.5\]\< 0.001KPS ≥ 70%14.2 \[7.9; 20.5\]\< 0.001CCI score−2.7 \[−5.2; −0.3\]0.030GH\
*N = 1321*\
*R*^*2*^ *= 0.15*Intercept63.9 \[58.4; 69.4\]\< 0.001Living alone−3.8 \[−6.4; −1.2\]0.004Disability pension−6.0\[−8.3; − 3.7\]\< 0.001Having felt a need for an esteem support−4.3 \[− 6.9; − 1.6\]0.002Having felt a need for an emotional support−3.2\[−5.9; − 0.6\]0.016Duration of transplantation−0.2 \[− 0.3; − 0.0\]0.03Treatment with cardiovascular drugs−4.9 \[− 7.1; − 2.7\]\< 0.001Treatment with ESA− 4.9 \[−8.1; − 1.7\]0.003Treatment with antidepressants− 4.3 \[− 7.9; − 0.7\]0.018KPS ≥ 70%10.0 \[5.3; 14.8\]\< 0.001High creatinine levels \> 250 (μmol/L)−6.9 \[−8.7; − 5.0\]\< 0.001SF\
*N = 1362*\
*R*^*2*^ *= 0.16*Intercept86.6 \[79.6; 93.7\]\< 0.001Living alone−5.1 \[−8.0; −2.1\]0.001Disability pension−2.6 \[−5.3; −0.0\]0.05Having felt a need for an esteem support−4.1 \[− 7.3; − 0.9\]0.011Having felt a need for an emotional support−7.8 \[−10.9; − 4.8\]\< 0.001Treatment with ESA−8.1 \[−11.8; − 4.5\]\< 0.001Treatment with calcium drugs−3.9 \[−6.4; − 1.4\]0.002Treatment with antidepressants−12.4 \[− 16.5; − 8.3\]\< 0.001KPS ≥ 70%8.4 \[2.9; 13.8\]0.003CCI score−0.9 \[−1.6; − 0.2\]0.01RE\
*N = 1257*\
*R*^*2*^ *= 0.15*Intercept72.5 \[62.4; 82.6\]\< 0.001Disability pension−6.4 \[−10.7; − 2.2\]0.003High monthly incomes (€)3.4 \[1.5; 5.3\]\< 0.001Having felt a need for an esteem support−7.0 \[−11.8; − 2.2\]0.004Having felt a need for an emotional support−5.9 \[−9.4; − 2.4\]\< 0.001Treatment with antidepressants−14.4 \[− 25.8; − 12.9\]\< 0.001KPS ≥ 70%13.3 \[5.0; 21.6\]0.002High creatinine levels \> 250 (μmol/L)−4.4 \[−7.7; − 1.1\]0.009MH\
*N = 1278*\
*R*^*2*^ *= 0.18*Intercept60.6 \[55.7; 65.5\]0.000Disability pension−5.9 \[−9.4; −2.4\]0.020High monthly incomes (€)2.7 \[1.8; 3.7\]\< 0.001Having felt a need for an esteem support−6.1 \[−8.7; − 3.6\]\< 0.001Having felt a need for an emotional support−5.1 \[− 7.6; −2.6\]\< 0.001Treatment with antidepressants−15.2 \[− 18.4; − 11.9\]\< 0.001KPS ≥ 70%7.8 \[3.6; 12.0\]\< 0.001VT\
*N = 1257*\
*R*^*2*^ *= 0.15*Intercept59.2 \[52.6; 65.7\]\< 0.001High monthly incomes (€)2.3 \[1.3; 3.3\]\< 0.001Having felt a need for an esteem support−4.4 \[−7.0; −1.8\]0.001Having felt a need for an emotional support−3.7 \[−6.2; − 1.2\]0.004Treatment with ESA−3.4 \[−6.5; −0.3\]0.03Treatment with calcium drugs−4.4 \[−6.5; −2.3\]\< 0.001Treatment with antidepressants−8.8 \[−12.3; −5.4\]\< 0.001KPS ≥ 70%8.0 \[3.4; 12.5\]0.001High creatinine levels \> 250 (μmol/L)−2.8 \[−4.6; −1.0\]0.002CCI score−0.8 \[−1.4; − 0.2\]0.007PCS\
*N = 1244*\
*R*^*2*^ *= 0.2*Intercept51.2 \[47.4; 54.8\]\< 0.001Age−0.1 \[− 0.1; − 0.0\]0.003Female−1.8 \[−2.8; − 0.7\]0.001Disability pension−2.7 \[−3.8; − 1.6\]\< 0.001High monthly incomes (€)−0.9 \[− 0.4; − 1.3\]\< 0.001Treatment with diabetic drugs− 2.5 \[−3.9; − 1.1\]\< 0.001Treatment with cardiovascular drugs− 1.4 \[− 2.4; − 0.3\]0.009Side effects related to any treatment−1.4 \[− 2.5; − 0.3\]0.012KPS ≥ 70%5.9 \[3.7; 8.0\]\< 0.001High creatinine levels \> 250 (μmol/L)−2.1 \[− 3.0; − 1.3\]\< 0.001CCI score− 0.7 \[− 1.1; − 0.3\]0.001MCS\
*N = 1268*\
*R*^*2*^ *= 0.18*Intercept49.6 \[47.9; 51.2\]\< 0.001High monthly incomes (€)1.3 \[0.8; 1.8\]\< 0.001Having felt a need for an esteem support−2.8 \[−4.1; −1.4\]\< 0.001Having felt a need for an emotional support−4.0 \[−5.4; − 2.7\]\< 0.001Treatment with calcium drugs−1.1 \[−2.2; −0.0\]0.044Treatment with antidepressants−7.3 \[−9.1; −5.5\]\< 0.001High creatinine levels \> 250 (μmol/L)−1.1 \[−2.0; −0.2\]0.015*β coeff* β coefficient, *ESA* Erythropoiesis-Stimulating Agent, *KPS* Karnofsky Performance Scale, *CCI* Charlson Comorbidity Index, *PF* Physical Functioning, *RP* Role Physical, *BP* Bodily Pain, *GH* General Health, *VT* Vitality, *SF* Social Functioning, *RE* Role Emotional, *MH* Mental Health, *PCS* Physical Component Score, *MCS* Mental Component ScoreTable 5Final regression models for ReTransQol domainsDimensionsVariablesβ coeff. \[95% CI\]*P* valuesPH\
*N = 1340*\
*R*^*2*^ *= 0.1*Intercept65.2 \[61.3; 69.0\]\< 0.001Employment status2.1 \[0.6; 3.5\]0.005Disability pension−2.8 \[−4.2; −1.5\]\< 0.001Having felt a need for an esteem support−3.1 \[−4.6; −1.6\]\< 0.001Having felt a need for an emotional support−1.7 \[− 3.3; −0.2\]0.022Treatment with cardiovascular drugs−1.7 \[−3.0; −0.4\]0.009Treatment with antidepressants−4.2 \[−6.2; −2.1\]\< 0.001Side effects related to any treatment−1.4 \[−2.8; −0.07\]0.04KPS ≥ 70%5.4 \[2.6; 8.1\]\< 0.001High creatinine levels \> 250 (μmol/L)−1.5 \[−2.6; −0.5\]0.003MH\
*N = 1276*\
*R*^*2*^ *= 0.1*Intercept77.5 \[73.7; 81.4\]\< 0.001Female−2.0 \[−3.8; −0.1\]0.034Living alone−5.1 \[−7.3; −3.0\]\< 0.001Disability pension−2.3 \[−4.3; −0.4\]0.015High monthly incomes (€)1.4 \[0.5; 2.4\]0.002Internet use5.4 \[0.2; 5.0\]0.03Having felt a need for an informative support2.1 \[0.2; 3.8\]0.024Treatment with antidepressants−7.0 \[−9.8; −4.0\]\< 0.001MC\
*N = 1355*\
*R*^*2*^ *= 0.1*Intercept78.2 \[76.9; 79.6\]\< 0.001Having felt a need for an informative support1.9 \[0.5; 3.4\]0.008Treatment with ESA−7.0 \[−9.8; −4.0\]0.06Treatment with calcium drugs−2.3 \[−3.7; −0.8\]0.001High creatinine levels \> 250 (μmol/L)− 2.0 \[− 3.1; − 0.7\]0.002TRT\
*N = 1347*\
*R*^*2*^ *= 0.1*Intercept86.8 \[82.2; 91.5\]\< 0.001High educational level−3.4 \[−6.1; −0.7\]0.011Having felt a need for an esteem support−4.2 \[− 6.3; −2.1\]\< 0.001Having felt a need for an informative support−3.1 \[−5.2; −1.1\]0.003Treatment with calcium drugs−2.2 \[−4.0; −0.5\]0.011Side effects related to any treatment−2.2 \[−4.1; −0.3\]0.023KPS ≥ 70%4.1 \[0.4; 7.7\]0.026High creatinine levels \> 250 (μmol/L)−3.1 \[−4.5; −1.8\]\< 0.001FG\
*N = 1259*\
*R*^*2*^ *= 0.1*Intercept70.4 \[66.1; 74.4\]\< 0.001Disability pension−4.0\[−6.2; −1.7\]0.001High monthly incomes (€)1.9 \[0.4; 2.9\]\< 0.001Having felt a need for an esteem support−4.1 \[−6.7; −1.6\]0.001Having felt a need for an emotional support−3.7 \[−6.3; −1.2\]0.004Being on dialysis before transplantation−4.8 \[−7.8; −1.7\]0.002Treatment with antidepressants−3.6 \[− 7.0; −0.2\]0.037High creatinine levels \> 250 (μmol/L)−3.7 \[−5.9; −2.1\]\< 0.001*β coeff* β coefficient, *ESA* Erythropoiesis-Stimulating Agent, *KPS* Karnofsky Performance Scale, *PH* Physical Health, *MH* Mental Health, *MC* Medical Care and satisfaction, *TRT* Treatment, *FG* Fear of losing the Graft

All HRQoL components of SF-36 and RTQ were lower with demographic and clinical characteristics. The variables which contributed most to low QoL scores were receiving disability pension, low monthly incomes and a low Karnofsky Performance Scale (\< 70%). To a lesser extent, advanced age, female gender, having children, unemployment, living alone, a high Charlson Comorbidity Index, high creatinine levels (\> 250 μmol/L), chronic graft dysfunction, being treated with cardiovascular drugs and presence of side effects related to treatments were associated with low QoL scores (Tables [4](#Tab4){ref-type="table"} and [5](#Tab5){ref-type="table"}).

Psycho-social variables were also found to be associated with HRQoL scores for both questionnaires. Perceived poor social support and being treated by antidepressants were associated with low scores of QoL, while internet access was associated with high QoL scores (Tables [4](#Tab4){ref-type="table"} and [5](#Tab5){ref-type="table"}).

Discussion {#Sec14}
==========

This study analyzed the factors associated with HRQoL in a representative sample of 1424 Kideny Transplant Recipients (KTR) from five kidney centers of France. This study goes further from a previous work published in a French national study of 1061 KTR from 8 regions of France, which was the first French report about HRQoL in kidney transplantation \[[@CR27]\]. We analyzed the exploration of psycho-social factors that were poorly studied in literature, such as perceived social support measured by a validated questionnaire \[[@CR22]\] and internet access. Indeed, there is growing evidence for the necessity of specifying psychological dimension's influence on quality of life after kidney transplantation \[[@CR35], [@CR36]\].

In our study, HRQoL scores, socio-demographic and clinical characteristics of KTR are similar to a French national survey \[[@CR27]\]. Socio-demographic variables had a negative influence on HRQoL: level of HRQoL significantly decreases with age, female gender, living status and the educational level. These findings are in accordance with other studies \[[@CR27], [@CR37]--[@CR52]\].

This study points out that KTR receiving a disability pension have an extremely impaired HRQoL, especially for physical dimensions. This association may be influenced by the impact of manual work \[[@CR53]\]. Patients in lower-ranked occupations may have less control in the work situation and thereby less possibility to prevent their health influenced by physical demands and poor ergonomic working environment \[[@CR54]\].

Karnofsky Performance Status (KPS) was strongly associated with good HRQoL scores, whatever the instrument used. Whether KTR could carry normal activity and take care of themselves are the important parameters of measurement of QoL. Zhang L et al. \[[@CR55]\] suggested that KPS score could be the most important factor associated with QoL values in patients with advanced HIV. These results suggest that healthy lifestyle and physical function are recommended after transplantation to improve HRQoL and it seems important to counsel and encourage for more physical activity as a part of routine medical care in KTR.

Furthermore, treatments with diabetic, cardiovascular and calcium drugs had a negative impact on HRQoL, especially for physical dimensions. In contrast, we did not find any association between immunosuppressive drugs and HRQoL, which suggests that nephrologists should use more effective treatments to prevent rejection and preserve the kidney function without adversely affecting HRQoL. A specific health education for KTR, including how treatments must be adhered, its benefits and side effects, is also recommended for KTR to handle difficulties due to specific treatments.

We also found a strong association between antidepressants and bad HRQoL scores for both physical and mental components. It is possible that patients treated with antidepressants tended to somatize more and give more emphasis to the negative effects of transplantation than its positive effects \[[@CR56], [@CR57]\]. It could also suggest that patients with worse health conditions are more susceptible to depression, even after transplantation. Studies reported that patients undergoing dialysis and/or transplantation, may become unable to cope with it, as it affects their mind integrity \[[@CR58]\]. Depression and anxiety as impaired HRQoL are known to be associated with increased mortality and poor outcomes in KTR \[[@CR59], [@CR60]\]. Mental health is thus playing an important role in HRQoL and should not be underestimated after kidney transplantation.

Aside from these factors, social support was significantly associated with bad HRQoL scores. KTR with a need for an esteem and emotional support have bad QoL scores in almost all dimensions and specifically in mental dimensions (Tables [4](#Tab4){ref-type="table"} and [5](#Tab5){ref-type="table"}). This underlies that social support may reflect non-constructive coping strategies with the disease, which should not be underestimated. Furthermore, informative support and internet access were associated with high QoL scores for mental dimension of ReTransQol (Table [5](#Tab5){ref-type="table"}), testifying their interest in seeking for information and communication about their health or their transplant, and arguing the need for progress in these fields. These results are in accordance with previous studies, which demonstrated that Internet could improve the well-being and QoL by providing mental stimulation and challenge \[[@CR61]\].

Summing up, these new findings reinforce the importance of patients' psychological health and strengthen the necessity of psychosocial development and support for these patients. Our patients may, after kidney transplantation, need more psychological interventions aiming to provide information about their medical care. This could help them to deal with their disease and reduce several mental problems (such as stress and anxiety). Therefore, for better post-transplant rehabilitation and given the risks of psychopathology, the development of interdisciplinary interventions such as socio-medical and psychotherapeutic programs are essential.

Finally, our sample is representative of general French KTR with a large sample size. To our knowledge, there are few studies with a sample over 1000 patients \[[@CR17], [@CR62], [@CR63]\]. Another strong point of the current study was the use of generic and specific HRQoL tools. We applied the generic instrument SF-36 Health Survey \[[@CR29], [@CR30]\], the most used questionnaire for HRQoL analysis in KTR \[[@CR64]--[@CR67]\], and a disease-specific instrument validated for KTR in the French language: the ReTransQol version 2 \[[@CR34]\]. Both questionnaires are very interesting to work with, as they are complementary and offer different views on the global aspects and the specific domains to identify factors associated with HRQoL for KTR. Indeed, RTQ was more sensitive than SF-36 for clinical variables such as treatment and fear of losing the graft, but less exhaustive for demographic factors. Another strong point of this study was the construction of a comprehensive multivariate model, including many variables, especially psycho-social ones that were poorly studied in QoL studies for KTR. Despite being comprehensive, the final regression models explained 20% of the physical (PCS) HRQoL variance and 18% of mental HRQoL variance (MCS). Limitations of our research are related to the cross-sectional design, which is the first phase of our longitudinal study, so we cannot truly interpret predictive factors. The longitudinal data are currently under analysis to compare HRQoL scores, its evolution over time and its associated factors.

Conclusion {#Sec15}
==========

The originality of our study's findings was that new variables, particularly KTR treated by antidepressants and having felt unmet needs for any social support, have a negative effect on their QoL. It may be useful to organize a psychological support specifically adapted for these patients. In order to orientate psychological programs and improve patient care and well-being, a better understanding of how patients anticipate, live and face post-kidney-transplantation and a deep investigation of psychological factors are needed in future QoL studies.
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